Janssen Ends Partnership with China's Hutchison MediPharma

Janssen Pharma, a Johnson & Johnson subsidiary, has ended an anti-inflammation collaboration with Hutchison MediPharma, the drug R&D arm of Hutchison China MediTech. HMP will continue to develop the collaboration's lead molecule, HMP-507, a small molecule candidate that targets a novel inflammation/immunology kinase. To date, HMP has received $13 million in upfront, milestone and development payments for the program. No reason was given for Janssen's decision. More details.... Stock Symbol: (NYSE: JNJ) (AIM: HCM) Share this with colleagues: // //